David A Janowick

6627767, Sep 30, 2003

Aug 22, 2001

09/934765

Gang Liu - Gurnee IL
Yihong Li - Carmel IN
David A. Janowick - Beach Park IL
Zhonghua Pei - Libertyville IL

Abbott Laboratories - Abott Park IL

C07C22900

560 19, 560 37, 562433, 562442

6972340, Dec 6, 2005

Aug 29, 2001

09/941471

Gang Liu - Gurnee IL, US
Bruce G. Szczepankiewicz - Lindenhurst IL, US
Zhonghua Pei - Libertyville IL, US
Zhili Xin - Lake Bluff IL, US
David A. Janowick - Beach Park IL, US

Abbott Laboratories - Abbott Park IL

C07C321/00
C07C271/00
C07C229/00
C07C069/76

560 41, 560 9, 560 24, 560 26, 560 27, 560 30, 560 33, 560 75, 560102, 560109, 560111, 560112, 560153

Compounds of formula (I) or therapeutically acceptable salts thereof, are selective protein tyrosine kinase-B (PTP1B) inhibitors. Preparation of the compounds, compositions containing the compounds, and treatment of disorders using the compounds are disclosed.

20020035137, Mar 21, 2002

Jul 31, 2001

09/918928

Gang Liu - Gurnee IL, US
Bruce Szczepankiewicz - Lindenhurst IL, US
Zhonghua Pei - Libertyville IL, US
Zhili Xin - Lake Bluff IL, US
Thorsten Oost - Pleasant Prairie WI, US
David Janowick - Beach Park IL, US

A61K031/66
C07D417/02
C07D413/02
C 07D 4 3/02
A61K031/506
A61K031/501
A61K031/497
A61K031/4439

514/360000, 514/362000, 514/364000, 514/369000, 514/372000, 514/376000, 514/380000, 514/381000, 514/386000, 514/114000, 514/252050, 514/255050, 514/256000, 514/340000, 544/238000, 544/333000, 544/322000, 544/405000, 546/268100, 546/269100, 546/274400, 546/271100, 546/272100, 546/276100, 548/122000, 548/134000, 548/132000, 548/187000, 548/243000, 548/253000, 548/319100, 548/366700

Compounds of formula (I) or therapeutically acceptable salts thereof, are protein tyrosine kinase PTPB inhibitors. Preparation of the compounds, compositions containing the compounds, and treatment of diseases using the compounds are disclosed.

20020169157, Nov 14, 2002

Feb 27, 2002

10/085157

Gang Liu - Gurnee IL, US
Zhili Xin - Lake Bluff IL, US
Zhonghua Pei - Libertyville IL, US
Xiaofeng Li - Gurnee IL, US
Bruce Szczepankiewicz - Lindenhurst IL, US
David Janowick - San Diego CA, US
Thorsten Oost - Pleasant Prairie WI, US

A61K031/55
A61K031/473
A61K031/47
A61K031/403

514/217000, 514/217010, 514/290000, 514/411000, 514/416000, 514/538000, 514/307000, 546/147000, 546/079000, 540/593000, 540/586000

Compounds of formula (I) or therapeutically acceptable salts thereof, are selective protein tyrosine kinase-B (PTP1B) inhibitors. Preparation of the compounds, compositions containing the compounds, and treatment of disorders using the compounds are disclosed.

62042939, Mar 20, 2001

May 7, 1998

9/073807

Said M. Sebti - Tampa FL
Andrew D. Hamilton - Guilford CT
David J. Augeri - Kenosha WI
Kenneth J. Barr - Chicago IL
Stephen A. Fakhoury - Mundelein IL
David A. Janowick - Beach Park IL
Douglas M. Kalvin - Buffalo Grove IL
Stephen J. O'Connor - Wilmette IL
Saul H. Rosenberg - Grayslake IL
Wang Shen - Gurnee IL
Rolf E. Swenson - Grayslake IL
Bryan K. Sorensen - Waukegan IL
Gerard M. Sullivan - Round Lake Beach IL
Andrew S. Tasker - Simi Valley CA
James T. Wasicak - Waterford WI
Lissa T. J. Nelson - Highland Park IL
Kenneth J. Henry - Fishers IN
Le Wang - Mundelein IL
Gang Liu - Gurnee IL
Indrani W. Gunawardana - Libertyville IL

University of Pittsburgh - Pittsburgh PA

C07C26302
C07C30300
A61K 3138

514570

Compounds having the formula ##STR1## or a pharmaceutically acceptable salt thereof wherein R. sub. 1 is (a) hydrogen, (b) loweralkyl, (c) alkenyl, (d) alkoxy, (e) thioalkoxy, (f) halo, (g) haloalkyl, (h) aryl-L. sub. 2 --, and (i) heterocyclic-L. sub. 2 --; R. sub. 2 is selected from ##STR2## (b) --C(O)NH--CH(R. sub. 14)--C(O)OR. sub. 15, ##STR3## (d) --C(O)NH--CH(R. sub. 14)--C(O)NHSO. sub. 2 R. sub. 16, (e) --C(O)NH--CH(R. sub. 14)-tetrazolyl, (f) --C(O)NH-heterocyclic, and (g) --C(O)NH--CH(R. sub. 14)--C(O)NR. sub. 17 R. sub. 18 ; R. sub. 3 is heterocyclic, aryl, substituted or unsubstituted cycloalkyl; R. sub. 4 is hydrogen, lower alkyl, haloalkyl, halogen, aryl, arylakyl, heterocyclic, or (heterocyclic)alkyl; L. sub. 1 is absent or is selected from (a) --L. sub. 4 --N(R. sub. 5)--L. sub. 5 --, (b) --L. sub. 4 --O--L. sub.

59624698, Oct 5, 1999

Nov 26, 1997

8/978971

Craig E. Thomas - West Chester OH
Thomas L. Fevig - West Chester OH
Stephen M. Bowen - Cincinnati OH
Robert A. Farr - Loveland OH
Albert A. Carr - Cincinnati OH
David A. Janowick - Beach Park IL

Hoechst Marion Roussel Inc. - Cincinnati OH

C07D22106
C07D49102
A61K 3144
A61K 3147

514301

The present invention is directed to novel cyclic nitrones and their use in the prevention of oxidation tissue damage by free radicals, their use in the treatment of a number of disease states in which radicals either damage or destroy tissues via oxidation, and pharmaceutical compositions containing these cyclic nitrones.

63100959, Oct 30, 2001

May 7, 1998

9/073794

Said M. Sebti - Tampa FL
Andrew D. Hamilton - Guilford CT
David J. Augeri - Kenosha WI
Kenneth J. Barr - Chicago IL
Stephen A. Fakhoury - Mundelein IL
David A. Janowick - Beach Park IL
Douglas M. Kalvin - Buffalo Grove IL
Stephen J. O'Connor - Wilmette IL
Saul H. Rosenberg - Grayslake IL
Wang Shen - Gurnee IL
Rolf E. Swenson - Grayslake IL
Bryan K. Sorenson - Waukegan IL
Gerard M. Sullivan - Round Lake Beach IL
Andrew S. Tasker - Simi Valley CA
James T. Wasicak - Waterford WI
Lissa T. J. Nelson - Highland Park IL
Kenneth J. Henry - Fishers IN
Le Wang - Mundelein IL

University of Pittsburgh - Pittsburgh PA

A61K 31192
C07C 53134

514539

Compounds having the formula ##STR1## or a pharmaceutically acceptable salt thereof wherein R. sub. 1 is (a) hydrogen, (b) loweralkyl, (c) alkenyl, (d) alkoxy, (e) thioalkoxy, (f) halo, (g) haloalkyl, (h) aryl-L. sub. 2 --, and (i) heterocyclic-L. sub. 2 --; R. sub. 2 is selected from (a) ##STR2## (b) --C(O)NH--CH(R. sub. 14)--C(O)OR. sub. 15, ##STR3## (d) --C(O)NH--CH(R. sub. 14)--C(O)NHSO. sub. 2 R. sub. 16, (e) --C(O)NH--CH(R. sub. 14)-tetrazolyl, (f) --C(O)NH-heterocyclic, and (g) --C(O)NH--CH(R. sub. 14)--C(O)NR. sub. 17 R. sub. 18 ; R. sub. 3 is substituted or unsubstituted heterocyclic or aryl, substituted or unsubstituted cycloalkyl or cycloalkenyl, ##STR4## and --P(W)R. sup. R3 R. sup. R3' ; R. sub. 4 is hydrogen, lower alkyl, haloalkyl, halogen, aryl, arylakyl, heterocyclic, or (heterocyclic)alkyl; L. sub. 1 is absent or is selected from (a) --L. sub. 4 --N(R. sub. 5)--L. sub.

20180009784, Jan 11, 2018

Jan 20, 2016

15/544192

- Cambridge MA, US
Kenneth M. Gigstad - Westford MA, US
David A. Janowick - Quincy MA, US
Hong Myung Lee - Cambridge MA, US
Zhan Shi - Concord MA, US
Francois Soucy - Stoneham MA, US
Stepan Vyskocil - Arlington MA, US

C07D 401/14
C07D 471/04
C07D 417/12
C07D 409/14
C07D 405/14
C07D 403/12
A61K 31/47
C07D 401/04
C07D 215/233
A61K 31/541
A61K 31/517
A61K 31/501
A61K 31/4709
C07D 401/12
C07D 495/04

This invention provides compounds of formula (I) or a pharmaceutically acceptable salt thereof, wherein T, J, R, R, R, o, R, W and Rand subsets thereof are as described in the specification. The compounds are inhibitors of NAMPT and are thus useful for treating cancer, inflammatory conditions, and/or T-cell mediated autoimmune disease.